Literature DB >> 11062565

Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase.

S Crennell1, T Takimoto, A Portner, G Taylor.   

Abstract

Paramyxoviruses are the main cause of respiratory disease in children. One of two viral surface glycoproteins, the hemagglutinin-neuraminidase (HN), has several functions in addition to being the major surface antigen that induces neutralizing antibodies. Here we present the crystal structures of Newcastle disease virus HN alone and in complex with either an inhibitor or with the beta-anomer of sialic acid. The inhibitor complex reveals a typical neuraminidase active site within a beta-propeller fold. Comparison of the structures of the two complexes reveal differences in the active site, suggesting that the catalytic site is activated by a conformational switch. This site may provide both sialic acid binding and hydrolysis functions since there is no evidence for a second sialic acid binding site in HN. Evidence for a single site with dual functions is examined and supported by mutagenesis studies. The structure provides the basis for the structure-based design of inhibitors for a range of paramyxovirus-induced diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062565     DOI: 10.1038/81002

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  197 in total

1.  Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.

Authors:  Helen Connaris; Toru Takimoto; Rupert Russell; Susan Crennell; Ibrahim Moustafa; Allen Portner; Garry Taylor
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site.

Authors:  Philip R Dormitzer; Zhen-Yu J Sun; Gerhard Wagner; Stephen C Harrison
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

3.  Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion.

Authors:  C J Russell; T S Jardetzky; R A Lamb
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion.

Authors:  Toru Takimoto; Garry L Taylor; Helen C Connaris; Susan J Crennell; Allen Portner
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Modes of paramyxovirus fusion: a Henipavirus perspective.

Authors:  Benhur Lee; Zeynep Akyol Ataman
Journal:  Trends Microbiol       Date:  2011-04-20       Impact factor: 17.079

6.  Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.

Authors:  Sompong Vongpunsawad; Numan Oezgun; Werner Braun; Roberto Cattaneo
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail.

Authors:  David L Waning; Charles J Russell; Theodore S Jardetzky; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

8.  Capture and imaging of a prehairpin fusion intermediate of the paramyxovirus PIV5.

Authors:  Yong Ho Kim; Jason E Donald; Gevorg Grigoryan; George P Leser; Alexander Y Fadeev; Robert A Lamb; William F DeGrado
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-16       Impact factor: 11.205

9.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

10.  Interacting domains of the HN and F proteins of newcastle disease virus.

Authors:  Kathryn A Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.